Sharemaestro company-news research for Zoetis Inc (ZTS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Provisional evidence
Company news sentiment
Latest ZTS news and sentiment
Zoetis Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
14 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone42/100
→
Published 30-day score49/100
Latest source headline
Zoetis Inc. (ZTS) Stock Price, News, Quote & History
Yahoo! Finance Canada · 24 Sep 2026 21:37
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
14 current stories are mapped specifically to ZTS.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.102.
Confidence is 23/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
23/100
Confidencethin evidence
78%/100
Company news14 company stories
98/100
Story agreement2/100 difference
News history
Daily score and story count over 30 days
29 Aug13 Sep27 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.102 after freshness weightingSource breadth60
3 independent publishersCompany relevance78
share tied directly to this companyFreshness43
recency-weighted evidenceAgreement98
how closely stories agreePublisher mix37
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks14 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202649USD 71.05-0.5%
18 Sep 202648USD 71.4-2.2%
11 Sep 202648USD 72.97-3.7%
04 Sep 202647USD 75.81-2.0%
28 Aug 202644USD 77.34-0.5%
21 Aug 202643USD 77.73+5.3%
14 Aug 202643USD 73.79+1.6%
07 Aug 202638USD 72.66-6.0%
Provisional evidence
News subjects
What is shaping the score
Earnings466 stories · 43%
Market update505 stories · 36%
Analyst action432 stories · 14%
Guidance501 stories · 7%
Source mix
Where the evidence comes from
Zacks442 stories · 14%
Business Wire502 stories · 14%
Simply Wall St.381 stories · 7%
Insider Monkey381 stories · 7%
CarePlus VietNam521 stories · 7%
Yahoo! Finance Canada501 stories · 7%
MarketBeat501 stories · 7%
Recurring subjects
Subjects appearing most often
Earnings8Price Target3Healthcare3Revenue Growth2Pharma2Medical2Life Sciences2Earnings Growth2Consensus Estimate2Animal Health2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
02 Jul50 neutral27 Sep 13:04
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 27 Sep 13:04 | 49 | +0 | 25/100 (-4) | 14 (0) | Provisional |
| 24 Sep 23:59 | 49 | +1 | 29/100 (+3) | 14 (-3) | Provisional |
| 18 Sep 23:59 | 48 | -1 | 26/100 (+8) | 17 (+1) | Provisional |
| 17 Sep 23:59 | 49 | +1 | 18/100 (-6) | 16 (-9) | Provisional |
| 10 Sep 23:59 | 48 | +1 | 24/100 (-1) | 25 (+1) | Provisional |
| 09 Sep 23:59 | 47 | +0 | 25/100 (-2) | 24 (-5) | Provisional |
| 08 Sep 23:59 | 47 | +1 | 27/100 (+4) | 29 (-24) | Provisional |
| 03 Sep 23:59 | 46 | +0 | 23/100 (-1) | 53 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 14 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings2 stories
87.9%0.0%
Analyst action1 story
12.1%0.0%
Each side uses the same scale: 0–87.9% of the retained directional evidence.
Where the influence comes from
78.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Zoetis Inc. (ZTS) Stock Price, News, Quote & History
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 21:37
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
43/100 tone
In the latest trading session, Zoetis (ZTS) closed at $70.27, marking a -1.87% move from the previous day. This move lagged the S&P 500's daily loss of 0.03%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq added 0.01%. Coming into today, shares of the animal health company had…
78% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
In the latest trading session, Zoetis (ZTS) closed at $70.27, marking a -1.87% move from the previous day. This move lagged the S&P 500's daily loss of 0.03%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq added 0.01%. Coming into today, shares of the animal health company had lost 7.62% in the past month. In that same time, the Medical sector lost 4.15%, while the S&P 500 gained 0.53%. The investment community will be paying close attention to the earnings performance of Zoetis in its upcoming release. It is anticipated that the company will report an EPS of $1.52, marking a 10.59
- Published
- 24 Sep 2026 21:15
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 44/100
- 30-day weight
- 78% of directional evidence · 2.7d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Consensus EstimateEarningsEarnings GrowthEstimate RevisionsMedicalValuation
—Unscored
EarningsNot used in direction
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
PARSIPPANY, N.J., September 24, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
PARSIPPANY, N.J., September 24, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is avail
- Published
- 24 Sep 2026 11:30
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.1d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Animal HealthEarningsFinancial Results
—Unscored
EarningsNot used in direction
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Zoetis (ZTS) was down 2.22% at $71.40. This change lagged the S&P 500's 0.17% gain on the day. Elsewhere, the Dow saw a downswing of 0.18%, while the tech-heavy Nasdaq appreciated by 0.4%. The animal health company's shares have seen a decrease of 2.67% over t…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
In the latest close session, Zoetis (ZTS) was down 2.22% at $71.40. This change lagged the S&P 500's 0.17% gain on the day. Elsewhere, the Dow saw a downswing of 0.18%, while the tech-heavy Nasdaq appreciated by 0.4%. The animal health company's shares have seen a decrease of 2.67% over the last month, not keeping up with the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%. Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.52, signifying a 10.59% drop compared to the same quarter of
- Published
- 18 Sep 2026 22:15
- News subject
- Earnings
- Why this score
- Negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.6d old
- Text assessed
- Stored article
- Duplicates
- 3 consolidated
Consensus EstimateEarningsEarnings GrowthMedicalPharmaPrice Target
38/100 tone
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and…
12.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay updated as the Fair Value for Zoetis shifts by adding it to your watchlist or portfolio. Alternatively, ex
- Published
- 18 Sep 2026 08:13
- News subject
- Analyst action
- Why this score
- Negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 12.1% of directional evidence · 9.2d old
- Text assessed
- Stored article
- Duplicates
- 3 consolidated
EarningsHealthcarePrice TargetRatings
—Unscored
GuidanceNot used in direction
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 18 Sep 2026 05:02
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Zoetis Stock: New Competition Changes The Story, But Not Yet The Rating (NYSE:ZTS)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 08:57
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Photo by Pexels on Pixabay If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Photo by Pexels on Pixabay If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses. Which Company Just Raised, And Which One Cut? Pfizer lifted the midpoint of its 2026 revenue guidance by $500 million while cutting its COVID-19 revenue expectation to about $4 billion from about $5 billion. The res
- Published
- 10 Sep 2026 17:05
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.8d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Balance SheetEarningsGrowthOperating IncomePharmaRevenue Growth
—Unscored
EarningsNot used in direction
Zoetis Shares Slide Following Earnings Revision - Revenue Growth Outlook
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 09 Sep 2026 07:00
- News subject
- Earnings
- Why this score
- Operating growth, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
38/100 tone
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the "Impax US Sustainable Economy Fund". The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Insti…
9.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the "Impax US Sustainable Economy Fund". The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at 17.92%, versus the index's 15.14%. Sector allocation and stock selection drove performance. The sustainability tools, including the Impax Sustainability Lens and Corporate Resilience framework, contributed positively. Equity markets rallied, wi
- Published
- 08 Sep 2026 14:51
- News subject
- Earnings
- Why this score
- Negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 9.9% of directional evidence · 18.9d old
- Text assessed
- Stored article
- Duplicates
- 3 consolidated
Animal HealthEarningsHedge FundsPharmaceuticalsSustainable Investing
—Unscored
Market updateNot used in direction
Is Zoetis Stock Underperforming the S&P 500?
Zoetis sign at their Canadian By JHVEPhoto Zoetis Inc. (ZTS) is the world's leading animal health company, developing, manufacturing, and commercializing vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. The Parsippany, New Je…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Zoetis sign at their Canadian By JHVEPhoto Zoetis Inc. (ZTS) is the world's leading animal health company, developing, manufacturing, and commercializing vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. The Parsippany, New Jersey-based company's products help veterinarians, livestock producers, and pet owners predict, prevent, detect, and treat diseases. It has a market capitalization of $31.9 billion. Companies worth $10 billion to $200 billion are generally described as "large-cap stocks," and Zoetis definitely fits that descrip
- Published
- 03 Sep 2026 11:56
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.0d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
EarningsHealthcarePrice TargetRevenue GrowthSpecialty Drug Manufacturers
—Unscored
EarningsNot used in direction
Zoetis (ZTS) Stock Still Looks Cheap As Earnings Expectations Stay Low
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Sep 2026 17:49
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
PARSIPPANY, N.J., September 02, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
PARSIPPANY, N.J., September 02, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis
- Published
- 02 Sep 2026 11:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.1d old
- Text assessed
- Stored article
- Duplicates
- 3 consolidated
ConferenceEarningsHealthcareLife Sciences
—Unscored
Market updateNot used in direction
Zoetis Inc. Class A (ZTS) Shareholding Pattern – Promoters, FIIs & DIIs
This article provides a detailed shareholding pattern for Zoetis Inc. Class A (ZTS), listing institutional investors with holdings greater than 1% across various quarters. It also includes recent insider trade data, specifically sell transactions by Ro Khanna and Gilbert Ray Cisneros, Jr.…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed shareholding pattern for Zoetis Inc. Class A (ZTS), listing institutional investors with holdings greater than 1% across various quarters. It also includes recent insider trade data, specifically sell transactions by Ro Khanna and Gilbert Ray Cisneros, Jr., and a buy transaction by Gilbert Ray Cisneros, Jr. The article further offers key financial metrics for ZTS, such as market cap, revenue, P/E ratio, P/B ratio, and dividend yield, as of August 28, 2026.
- Published
- 28 Aug 2026 16:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
Earlier company news
ZTS news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 127 older ZTS headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ZTS, but the headline and available text are not mainly about Zoetis Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ZTS sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.